Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer

• Автори: Benjamin K. Schneider (Автор), Arnaud Boyer (Автор), Joseph Ciccolini (Автор), Fabrice Barlesi (Автор), Kenneth Wang (Автор), Sebastien Benzekry (Автор), Jonathan P. Mochel (Автор)
• Формат: Книга
• Опубліковано: Wiley, 2019-08-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Bevacizumab‐pemetrexed/cisplatin (BEV‐PEM/CIS) is a first‐line therapeutic for advanced nonsquamous non‐small cell lung cancer. Bevacizumab potentiates PEM/CIS cytotoxicity by inducing transient tumor vasculature normalization. BEV‐PEM/CIS has a narrow therapeutic window. Therefore, it is an attract...